Development and Validation of UV Spectrophotometry and Liquid Chromatography Methods for Determination of Cefpirome in Raw Material and Pharmaceutical Dosage

Tércio Paschke Oppe; Júlia Menegola; Elfrides Eva Scherman Schapoval

doi:10.22456/2527-2616.93809

Authors

Tércio Paschke Oppe Faculdade de Farmácia - Universidade Federal do Rio Grande do Sul
Júlia Menegola Faculdade de Farmácia - Universidade Federal do Rio Grande do Sul
Elfrides Eva Scherman Schapoval Faculdade de Farmácia - Universidade Federal do Rio Grande do Sul

DOI:

https://doi.org/10.22456/2527-2616.93809

Keywords:

cefpirome, UV spectrophotometry, liquid chromatography, method validation, stability

Abstract

In the present work, analytical methods, UV Spectrophotometry and Liquid Chromatography (HPLC), were developed and validated for quantification of cefpirome, a broad-spectrum fourth-generation cephalosporin, in raw material and powder for injectable preparation. The UV spectrophotometric method was performed at 271 nm, using 0.1 M hydrochloric acid as solvent. The HPLC was carried out using Techsphere ODS column and mobile phase consisted of methanol-water (30:70, v/v) with flow rate 0.8 mL/min and UV detection at 265 nm. The validation method yielded good results demonstrated statistically that the methods were linear, precise, accurate, specific and robust. A preliminary stability study of cefpirome showed that the UV Spectrophotometry and Liquid Chromatography methods were specific for the determination cefpirome in the presence of its degradation products. No statistically difference was observed between the proposed methods. The UV Spectrophotometry and Liquid Chromatography methods allow the quantitation of cefpirome in pharmaceutical dosage form and raw material and can be used for the drug analysis in routine quality control.

Downloads

Download data is not yet available.

References

art nez LG, Falcó PC, Cabeza AS. Comparison of several methods used for the determination of cephalosporins. Analysis of cephalexin in pharmaceutical samples. J Pharm Biomed Anal. 2002; 305-423.

Tumah H. Fourth-generation cephalosporins: in vitro activity against nosocomial gram-negative bacilli compared with beta-lactam antibiotics and ciprofloxacin. Chemotherapy. 2005; 51:80-85.

Lima B, Bodeau S, Quinton MC, Leven C, LemaireHurtel AS, Bennis Y. Validation and Application of an HPLC-DAD Method for Routine Therapeutic Drug Monitoring of Ceftobiprole. Antimicrobial Agents and Chemotherapy [serial online] 2019 July; 63(7):[6 screens]. Available from: URL:https://aac.asm.org/content/63/7/e00515-19.

The Merck Index 15th Ed., Royal Society of Chemistry: Cambridge; 2013.

Wiseman LR, Lamb HM. Cefpirome. A Review of its Antibacterial Activity, Pharmacokinetic Properties and Clinical Efficacy in the Treatment of Severe Nosocomial Infections and Febrile Neutropenia. Drugs. 1997; 54:117-140.

Tumah, HN. In vitro activity of cefepime and cefpirome compared to other third-generation cephem antibiotics against gram-negative nosocomial pathogens. Pharmazie. 2004; 59: 854-858.

Roos JF, Lipma J, Kirkpatrick CM. Population pharmacokinetics and pharmacodynamics of cefpirome in critically ill patients against Gram-negative bacteria. Intensive Care Med. 2007; 7:781-788.

Hollenstein U, Brumnner M, Mayer B, Delacher S, Erovic B, Eichler HG, et al. Target site concentrations after continuous infusion and bolus injection of cefpirome to healthy volunteers. Clinical Pharmacology & Therapeutics. 2000; 67: 229-236.

Joukhadar C, Klein N, Mayer BX, Kreischitz N, DelleKarth G, Palkovits P, et al. Plasma and tissue pharmacokinetics of cefpirome in patients with sepsis. Critical Care Medicine. 2002, 30:1478-1482.

Mlynarczyk G, Mlynarczyk A, Bilewska A, Dukaczewska A, Golawski C, Kicman A, et al. High effectiveness of the method with cefpirome in detection of extended-spectrum beta-lactamases in different species of gram-negative bacilli. Medycyna Doswiadczalna I Mikrobiologia. 2006; 58:59-65.

Mrestani Y, Hartl A, Neubert RH. Influence of absorption enhancers on the pharmacokinetic properties of non-oral beta-lactam-cefpirom using the rabbit (Chinchilla) in vivo model. International Journal of Phamaceutics. 2006; 309:67-70.

Rajput N, Dumka VK, Sandhu HS. Disposition kinetics and urinary excretion of cefpirome after intravenous injection in buffalo calves. J Vet Scien. 2007; 8:21-25.

Nikolovski M, Kotsev IU, Panchev P, Treatment with cefrom (cefpirom) in severe urological infections. Khirurgiia (Sofiia). 2004; 60:39-41.

Oppe TP, Menegola J. Schapoval EES. Microbiological assay for the determination of cefpirome in raw material and injectable preparation. Drug analytical research. 2018, 2:29-35.

Zalewski P, Skibiński R, Cielecka-Piontek J, BednarekRajewska K. Development and validation of stabilityindicating HPLC method for determination of cefpirome sulfate. Acta Pol Pharm. 2014; 71:731-736.

Vikas JR. Voltammetric determination of cefpirome at multiwalled carbon nanotube modified glassy carbon sensor based electrode in bulk form and pharmaceutical formulation. Colloids Surf B Biointerfaces. 2011; 87:423-426.

Sriwiriyajan S, Mahatthanatrakul W. Development of an analytical method for cefpirome in plasma by simplified HPLC technique and its applications. Arzneimittelforschung. 2010; 60:336-933.

Arayne MS, Sultana N, Nawaz M. A rp-HPLC method for the assay of cefpirome and its application in drugmetal interaction studies. Pak J Pharm Sci. 2006 ;19:39- 44.

Evagelou V, Tsantili-Kaloulidou A, Koupparis M, Determination of the Dissociation Constants of the Cephalosporins Cefepime and Cefpirome using UV Spectrometry and pH Potentiometry. J Pharm Biomed Anal. 2003; 31:1119-1128.

International Conference on Harmonization (ICH), Validation of Analytical Procedures: Text and Methodology, Q2 (R1), 2005.

The United States Pharmacopeia 42th ed. Rochville: United States Pharmacopoeial Convention, 2019.

AOAC, Official Methods of Analytical Chemists of AOAC, 15th ed. XVII, 1990.

Ermer, J. Validation in Pharmaceutical Analysis. Part I: An Integrated Approach. Journal of Pharmaceutical and Biomedical Analysis, v. 24, p. 755-767, 2001.

Leito S, Mölder K, Künnapas A, Herodes K, Leito I. Uncertainty in liquid chromatographic analysis of pharmaceutical product: Influence of various uncertainty sources. J. Chromatogr. A. 2006; 1121:55-63.

Rauber C.S, Guterres SS, Schapoval EES. LC determination of citral in Cymbopogon citratus volatile oil. J. Pharm. Biomed. Anal. 2005; 37:597-601.

Costa MCN, Barden AT, Andrade JMM, Oppe TP, Schapoval EES. Quantitative evaluation of besifloxacin ophthalmic suspension by HPLC, application to bioassay method and cytotoxicity studies. Talanta.119:367-374.